Literature DB >> 31850650

Evidence-based psychotherapy trends among posttraumatic stress disorder patients in a national healthcare system, 2001-2014.

Shira Maguen1,2, Nicholas Holder1,2, Erin Madden1, Yongmei Li1, Karen H Seal3,4, Thomas C Neylan1,2, Callan Lujan1, Olga V Patterson5,6, Scott L DuVall5,6, Brian Shiner7,8.   

Abstract

BACKGROUND: Although evidence-based psychotherapies (EBPs) for posttraumatic stress disorder (PTSD) were implemented starting in 2005 in the veterans health administration (VHA), the largest national healthcare system in the U.S., the rate of initiation (uptake) and prevalence of these treatments in each calendar year have not been determined. We aimed to elucidate two metrics of EBP utilization, uptake and prevalence, following implementation.
METHODS: Cohort study of Iraq and Afghanistan veterans in VHA (N = 181,620) with a PTSD diagnosis and ≥1 psychotherapy-coded outpatient visit from 2001 to 2014. Using natural language processing techniques, annual and cumulative uptake and prevalence rates from 2001 to 2014 were calculated for each of the two EBPs for PTSD, cognitive processing therapy (CPT) and prolonged exposure (PE) therapy.
RESULTS: Annual uptake of CPT increased during most years, reaching a maximum of 11.1%. Annual uptake of PE showed little change until 2008 and then increased, reaching a maximum of 4.4%. The annual prevalence of CPT increased throughout the study, reaching a maximum of 14.6%. The annual prevalence of PE increased to a maximum of 5.0% in 2010, but then flattened and declined. Annual uptake of minimally adequate CPT increased a to maximum of 5% in 2014. Annual uptake of minimally adequate PE increased to a maximum of 1.2% in 2010. The cumulative prevalence of CPT was 19.9% and cumulative prevalence for PE was 7.5%.
CONCLUSIONS: Access to EBPs for PTSD modestly increased for Iraq and Afghanistan veterans after nationwide implementation efforts. Further expanding the reach to veterans is critical, given low rates of minimally adequate EBPs for PTSD. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  cognitive therapy; natural language processing; posttraumatic; prevalence; stress disorders; veterans

Mesh:

Year:  2019        PMID: 31850650     DOI: 10.1002/da.22983

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  5 in total

1.  Improving function through primary care treatment of PTSD: The IMPACT study protocol.

Authors:  Sheila A M Rauch; H Myra Kim; Ron Acierno; Carly Ragin; Bethany Wangelin; Kimberly Blitch; Wendy Muzzy; Stephanie Hart; Kara Zivin; Jeffrey Cigrang
Journal:  Contemp Clin Trials       Date:  2022-08-12       Impact factor: 2.261

2.  Adapting a family-involved intervention to increase initiation and completion of evidenced-based psychotherapy for posttraumatic stress disorder.

Authors:  Megan Shepherd-Banigan; Stephanie Y Wells; Margaret Falkovic; Princess E Ackland; Cindy Swinkels; Eric Dedert; Rachel Ruffin; Courtney H Van Houtven; Patrick S Calhoun; David Edelman; Hollis J Weidenbacher; Abigail Shapiro; Shirley Glynn
Journal:  SSM Ment Health       Date:  2022-05-18

3.  Family Involvement in PTSD Treatment: Perspectives from a Nationwide Sample of Veterans Health Administration Clinicians.

Authors:  Johanna Thompson-Hollands; Alora A Rando; Sarah A Stoycos; Laura A Meis; Katherine M Iverson
Journal:  Adm Policy Ment Health       Date:  2022-08-05

4.  Natural language processing in clinical neuroscience and psychiatry: A review.

Authors:  Claudio Crema; Giuseppe Attardi; Daniele Sartiano; Alberto Redolfi
Journal:  Front Psychiatry       Date:  2022-09-14       Impact factor: 5.435

5.  Neural response to trauma-related and trauma-unrelated negative stimuli in remitted and persistent pediatric post-traumatic stress disorder.

Authors:  Peng Wang; Zu-Lai Peng; Lu Liu; Li An; Yu-Xin Liu; Qing-Jiu Cao; Li Sun; Ning Ji; Yun Chen; Bin-Rang Yang; Yu-Feng Wang
Journal:  Brain Behav       Date:  2021-06-02       Impact factor: 2.708

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.